Canton Hathaway LLC Buys 26,565 Shares of Boston Scientific Corporation $BSX

Canton Hathaway LLC purchased a new position in Boston Scientific Corporation (NYSE:BSX - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 26,565 shares of the medical equipment provider's stock, valued at approximately $1,160,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Murphy Pohlad Asset Management LLC bought a new stake in Boston Scientific in the third quarter valued at $1,100,000. Outfitters Financial LLC boosted its position in shares of Boston Scientific by 4.3% during the 3rd quarter. Outfitters Financial LLC now owns 30,527 shares of the medical equipment provider's stock worth $1,333,000 after purchasing an additional 1,250 shares in the last quarter. Fifth Third Wealth Advisors LLC boosted its position in shares of Boston Scientific by 21.2% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 49,387 shares of the medical equipment provider's stock worth $2,156,000 after purchasing an additional 8,631 shares in the last quarter. Sterling Capital Management LLC grew its stake in shares of Boston Scientific by 1,344.7% in the 3rd quarter. Sterling Capital Management LLC now owns 84,691 shares of the medical equipment provider's stock valued at $3,697,000 after buying an additional 78,829 shares during the period. Finally, MBL Wealth LLC grew its stake in shares of Boston Scientific by 306.0% in the 3rd quarter. MBL Wealth LLC now owns 25,191 shares of the medical equipment provider's stock valued at $1,100,000 after buying an additional 18,987 shares during the period. 89.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently commented on BSX. Robert W. Baird set a $56.00 target price on Boston Scientific in a research report on Thursday, July 30th. BTIG Research cut their price target on Boston Scientific from $60.00 to $56.00 and set a "buy" rating on the stock in a report on Wednesday, September 9th. Raymond James Financial reiterated an "outperform" rating and issued a $57.00 price target (down from $78.00) on shares of Boston Scientific in a report on Thursday, July 30th. Argus reissued a "hold" rating on shares of Boston Scientific in a research note on Friday, July 31st. Finally, Mizuho set a $55.00 price objective on Boston Scientific in a report on Tuesday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $68.23.

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael F. Mahoney acquired 186,240 shares of the stock in a transaction dated Monday, August 3rd. The stock was purchased at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the purchase, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. This trade represents a 13.27% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig bought 5,000 shares of the company's stock in a transaction dated Friday, July 31st. The stock was bought at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the acquisition, the director directly owned 30,359 shares of the company's stock, valued at approximately $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders purchased 194,522 shares of company stock worth $9,385,210. Insiders own 0.34% of the company's stock.

Boston Scientific Stock Down 0.7%

Shares of NYSE BSX opened at $45.67 on Friday. The stock has a market capitalization of $66.19 billion, a P/E ratio of 18.49, a P/E/G ratio of 1.10 and a beta of 0.58. The company has a 50-day moving average price of $45.46 and a 200-day moving average price of $49.16. Boston Scientific Corporation has a 1 year low of $41.38 and a 1 year high of $105.65. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the previous year, the firm posted $0.75 earnings per share. The firm's revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts forecast that Boston Scientific Corporation will post 3.24 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.